# Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

> **NCT04091490** · PHASE2 · COMPLETED · sponsor: **State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia** · enrollment: 40 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04091490
- **Lead sponsor:** State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-19
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091490, "Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04091490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*